IndexIQ Advisors LLC raised its position in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 15.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,298 shares of the medical research company’s stock after purchasing an additional 438 shares during the quarter. IndexIQ Advisors LLC’s holdings in Exact Sciences were worth $230,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of EXAS. Nikko Asset Management Americas Inc. raised its position in Exact Sciences by 29.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 5,418,800 shares of the medical research company’s stock valued at $412,750,000 after purchasing an additional 1,218,384 shares during the last quarter. ARK Investment Management LLC increased its stake in shares of Exact Sciences by 6.1% in the first quarter. ARK Investment Management LLC now owns 14,323,962 shares of the medical research company’s stock valued at $1,001,531,000 after buying an additional 827,948 shares during the period. Spyglass Capital Management LLC increased its stake in shares of Exact Sciences by 18.3% in the fourth quarter. Spyglass Capital Management LLC now owns 2,669,716 shares of the medical research company’s stock valued at $207,784,000 after buying an additional 413,713 shares during the period. Ensign Peak Advisors Inc increased its stake in shares of Exact Sciences by 20.5% in the fourth quarter. Ensign Peak Advisors Inc now owns 2,388,812 shares of the medical research company’s stock valued at $185,922,000 after buying an additional 406,554 shares during the period. Finally, Bellevue Group AG increased its stake in shares of Exact Sciences by 49.7% in the fourth quarter. Bellevue Group AG now owns 642,582 shares of the medical research company’s stock valued at $50,012,000 after buying an additional 213,309 shares during the period. 94.45% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, Director Katherine S. Zanotti sold 1,086 shares of the firm’s stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $40.13, for a total value of $43,581.18. Following the completion of the sale, the director now owns 60,318 shares of the company’s stock, valued at…